Your browser doesn't support javascript.
loading
Consensus report: Definition and interpretation of remission in type 2 diabetes.
Riddle, Matthew C; Cefalu, William T; Evans, Philip H; Gerstein, Hertzel C; Nauck, Michael A; Oh, William K; Rothberg, Amy E; le Roux, Carel W; Rubino, Francesco; Schauer, Philip; Taylor, Roy; Twenefour, Douglas.
Afiliação
  • Riddle MC; Division of Endocrinology, Diabetes, & Clinical Nutrition, Department of Medicine, Oregon Health & Science University, Portland, OR.
  • Cefalu WT; Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
  • Evans PH; College of Medicine and Health, University of Exeter, Exeter, UK.
  • Gerstein HC; Population Health Research Institute and Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • Nauck MA; Diabetes Division, Katholisches Klinikum Bochum gGmbH, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.
  • Oh WK; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Rothberg AE; Department of Internal Medicine, Michigan Medicine, and Department of Nutritional Sciences, School of Public Health, University of Michigan, Ann Arbor, MI.
  • le Roux CW; Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland.
  • Rubino F; Department of Diabetes, School of Life Course Sciences, King's College London, London, UK.
  • Schauer P; Pennington Biomedical Research Center, Baton Rouge, LA.
  • Taylor R; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Twenefour D; Diabetes UK, London, UK.
Diabet Med ; 39(3): e14669, 2022 03.
Article em En | MEDLINE | ID: mdl-34460965
ABSTRACT
Improvement of glucose levels into the normal range can occur in some people living with diabetes, either spontaneously or after medical interventions, and in some cases can persist after withdrawal of glucose-lowering pharmacotherapy. Such sustained improvement may now be occurring more often due to newer forms of treatment. However, terminology for describing this process and objective measures for defining it are not well established, and the long-term risks versus benefits of its attainment are not well understood. To update prior discussions of this issue, an international expert group was convened by the American Diabetes Association to propose nomenclature and principles for data collection and analysis, with the goal of establishing a base of information to support future clinical guidance. This group proposed "remission" as the most appropriate descriptive term, and HbA1c <6.5% (48 mmol/mol) measured at least 3 months after cessation of glucose-lowering pharmacotherapy as the usual diagnostic criterion. The group also made suggestions for active observation of individuals experiencing a remission and discussed further questions and unmet needs regarding predictors and outcomes of remission.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Guias de Prática Clínica como Assunto / Diabetes Mellitus Tipo 2 / Endocrinologia Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Guias de Prática Clínica como Assunto / Diabetes Mellitus Tipo 2 / Endocrinologia Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article